

Supporting Information for

Silver-Catalyzed Decarboxylative Bromination of Aliphatic Carboxylic Acids

Xinqiang Tan, Tao Song, Zhentao Wang, He Chen, Lei Cui, and Chaozhong Li*

Key Laboratory of Organofluorine Chemistry and Collaborative Innovation Center of Chemistry for Life Sciences, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China, and School of Chemical Engineering, Ningbo University of Technology, No. 89 Cuibai Road, Ningbo 315016, China

E-mail: clig@mail.sioc.ac.cn

Table of Contents

1. General Information.	S2
2. Synthesis of Substrates.	S2 – S3
3. Typical Procedure for Decarboxylative Bromination.	S3 – S4
4. Characterizations of New Products.	S4 – S11
5. References for Known Compounds.	S11 – S12
6. ¹H and ¹³C NMR Spectra of All Products.	S12 – S33


1. General Information.

All reagents were obtained commercially unless otherwise noted. Dichloromethane, 1,2-dichloroethane, acetonitrile were distilled over calcium hydride prior to use. All reactions were performed using standard schlenk techniques under argon. Purification of products was accomplished using flash chromatography on silica gel 60 (40-63 μm). Thin layer chromatography was performed on silica gel 60 F₂₅₄ plates (250 μm). Nuclear magnetic resonance (NMR) spectra were recorded on a Agilent 400 or Bruker 400 instrument operating at 400, 100, and 376 MHz for ^1H , ^{13}C , ^{19}F , respectively. Chemical shifts were reported in δ ppm referenced to an internal SiMe₄ standard for ^1H NMR, chloroform-d (δ 77.00) for ^{13}C NMR. Multiplicities were reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. High-resolution mass data were recorded on a high-resolution mass spectrometer in the EI mode.

2. Synthesis of Substrates

The following substrates were commercially available and recrystallized prior to use: 2-methyl-4-oxo-4-phenylbutanoic acid (**1d**), 1-adamantanecarboxylic acid (**1i**), 2-(2-iodophenyl)acetic acid (**1m**), 2-(3-bromophenyl)acetic acid (**1n**), 2-(3-(trifluoromethoxy)phenyl)acetic acid (**1o**), 2-(4-(tert-butyl)phenyl)acetic acid (**1p**), 2-([1,1'-biphenyl]-4-yl)acetic acid (**1q**), 2-(p-tolyl)acetic acid (**1r**), 2-phenylbutanoic acid (**1t**), 2-cyclohexyl-2-phenylacetic acid (**1v**), 11-bromoundecanoic acid (**1z**), 2,2-dimethylpentanedioic acid (**6**). The rest substrates were known compounds (except **1h**) and readily prepared by conventional methods.

Characterizations of New Substrates:



(1-(4-(Trifluoromethyl)benzoyl)piperidine-4-carboxylic acid. This compound was prepared by reaction of 4-trifluoromethylbenzoyl chloride with ethyl piperidine-4-carboxylate followed by hydrolysis under basic conditions. Yield: 1.37 g (91% over two steps). White solid, mp: 152–154 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.85 (br, 1H), 7.68 (d, *J* = 8.0 Hz, 2H), 7.51 (d, *J* = 8.0 Hz, 2H), 4.51 (br, 1H), 3.65 (br, 1H), 3.11 (br, 2H), 2.67–2.50 (m, 1H), 2.07 (br, 1H), 1.87 (br, 1H), 1.81 (br, 1H), 1.69 (br, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 179.0, 169.2, 139.2, 131.8 (q, *J* = 32.0 Hz), 127.2, 125.7 (q, *J* = 3.6 Hz), 123.7 (q, *J* = 271.0 Hz), 46.8, 41.5, 40.5, 28.2, 27.6; ¹⁹F NMR (376 MHz, CDCl₃): δ -62.9 (s, 3F); IR (KBr): ν (cm⁻¹) 2956, 1729, 1602, 1450, 1326, 1169, 1126, 1065, 849, 735; EIMS: *m/z* (rel intensity) 301 (M⁺, 47), 300 (84), 282 (9), 254 (10), 228 (6), 173 (100), 145 (48), 128 (23), 95 (5), 82 (6); HRMS calcd for C₁₄H₁₄F₃NO₃ [M]: 301.0926; found: 301.0929.


3. Typical Procedure for Decarboxylative Bromination.

3-Bromopentadecane (3a). Typical Procedure. To a 20 mL schlenk tube equipped with a stir bar were added 2-ethyltetradecanoic acid (**1a**, 51 mg, 0.2 mmol), Ag(Phen)₂OTf (3 mg, 0.005 mmol) and dibromoisocyanuric acid (**2c**, 46 mg, 0.16 mmol) under argon atmosphere. 1, 2-Dichloroethane (8 mL) was then added. The Schlenk tube was sealed and stirred at room temperature for 24 h. Thin layer chromatography (TLC) indicated that the starting material **1a** was all consumed. The reaction mixture was filtered. The white precipitate was washed with CH₂Cl₂ (3 × 2 mL) and dried. Isocyanuric acid was thus obtained as a white solid. Yield: 18 mg (90% based on **2c**). The combined organic phase was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether/ EtOAc = 50:1) to afford the pure product 3-bromopentadecane (**3a**) as a colorless oil. Yield: 51 mg (88%). ¹H NMR (400 MHz, CDCl₃): δ 4.02–3.96 (m, 1H), 1.90–1.78 (m, 4H), 1.52 (br, 1H), 1.41 (br, 1H), 1.26 (br, 18H), 1.04 (t, *J* = 7.2

Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 60.6, 38.8, 32.2, 31.9, 29.69, 29.66, 29.60, 29.5, 29.4, 29.1, 27.6, 22.7, 14.1, 12.1; IR (neat): ν (cm^{-1}) 2924, 2853, 1462, 1379, 797, 721; EIMS: m/z (rel intensity) 211 (32), 155 (7), 141 (11), 127 (14), 113 (16), 99 (27), 85 (72), 71 (90), 57 (100), 43 (45), 41 (34); HRMS calcd for $\text{C}_{15}\text{H}_{31}[\text{M}-\text{Br}]$: 211.2426; found: 211.2431.


Typical Procedure at 1.0 mmol Scale. To a 100 mL 3-necked flask were added 2-ethyltetradecanoic acid (**1a**, 256 mg, 1.0 mmol), $\text{Ag}(\text{Phen})_2\text{OTf}$ (11 mg, 0.025 mmol) and dibromoisocyanuric acid (**2c**, 230 mg, 0.80 mmol) under argon atmosphere. 1, 2-Dichloroethane (40 mL) was then added. The mixture was stirred at room temperature for 24 h. Thin layer chromatography (TLC) indicated that the starting material **1a** was all consumed. The resulting mixture was filtered. The white precipitate was washed with CH_2Cl_2 (3×5 mL) and dried. Isocyanuric acid was thus obtained as a white solid. Yield: 94 mg (91% based on **2c**). The combined organic phase was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether/ EtOAc = 50:1) to afford the pure product 3-bromopentadecane (**3a**) as a colorless oil. Yield: 250 mg (86%).

4. Characterizations of New Products.




(2-Bromopropane-1,3-diyl)dicyclohexane. Yield: 52 mg (91%). Colorless oil; ^1H NMR (400 MHz, CDCl_3): δ 4.24-4.16 (m, 1H), 1.82-1.51 (m, 16H), 1.33-1.08 (m, 6H), 1.02-0.90 (m, 2H), 0.88-0.75 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 54.0, 47.4, 35.7, 33.6, 32.2, 26.6, 26.2, 26.0; IR (neat): ν (cm^{-1}) 2922, 2851, 1447, 1276, 1233, 1168, 937, 890, 844; EIMS: m/z (rel intensity) 207 (82), 151 (10), 137 (14), 125 (42), 111 (97), 97 (97), 83 (100), 69 (44), 55 (76), 41 (27); HRMS calcd for $\text{C}_{15}\text{H}_{27}[\text{M}-\text{Br}]$:


207.2113; found: 207.2109.



1-(2-Bromobutyl)-4-nitrobenzene. Yield: 35 mg (68%). Colorless oil; ^1H NMR (400 MHz, CDCl_3): δ 8.19 (d, $J = 8.4$ Hz, 2H), 7.39 (d, $J = 8.4$ Hz, 2H), 4.18-4.11 (m, 1H), 3.33-3.18 (m, 2H), 2.00-1.80 (m, 2H), 1.11 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 147.0, 146.1, 130.1, 123.6, 57.8, 44.8, 31.8, 12.1; IR (neat): ν (cm^{-1}) 2969, 2935, 1605, 1519, 1346, 1109, 1019, 856, 745, 698; EIMS: m/z (rel intensity) 259 (10), 257 (M^+ , 11), 178 (50), 136 (51), 117 (35), 106 (24), 90 (23), 89 (20), 78 (22); HRMS calcd for $\text{C}_{10}\text{H}_{12}\text{BrNO}_2$ [M]: 257.0051; found: 257.0050.




1,6-Dibromooctane. Yield: 50 mg (93%). Colorless oil; ^1H NMR (400 MHz, CDCl_3): δ 4.02–3.94 (m, 1H), 3.42 (t, $J = 6.8$ Hz, 2H), 1.92–1.78 (m, 6H), 1.62-1.41 (m, 4H), 1.04 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 60.2, 38.5, 33.7, 32.6, 32.2, 27.6, 26.8, 12.1; IR (neat): ν (cm^{-1}) 2964, 2936, 2858, 1460, 1433, 1239, 896, 797, 732, 650; EIMS: m/z (rel intensity) 273 (6), 271 (12), 269 (6), 191 (46), 149 (18), 135 (15), 111 (73), 109 (47), 69 (100), 57 (38), 55 (69), 41 (53); HRMS calcd for $\text{C}_8\text{H}_{15}\text{Br}_2$ [$\text{M}-\text{H}$]: 268.9540; found: 268.9538.




2-((4-Bromocyclohexyl)methyl)isoindoline-1,3-dione. This compound was isolated as the mixture of two stereoisomers in about 1:1 ratio determined by ^1H NMR (400 MHz). Yield: 49 mg (76%). White solid, mp: 96-98 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) (mixture of two stereoisomers): δ 7.87-7.82 (m, 2H), 7.75-7.70 (m, 2H), 4.60 (t, $J =$

2.8 Hz, 0.5H), 4.02–3.93 (m, 0.5H), 3.62 (d, $J = 7.2$ Hz, 1H), 3.53 (d, $J = 7.2$ Hz, 1H), 2.36–2.26 (m, 1H), 2.14–2.06 (m, 1H), 1.94–1.52 (m, 6H), 1.25–1.10 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 168.5, 134.0/133.9, 132.0/131.9, 123.3/123.2, 53.6/51.3, 43.3/43.2, 37.2/36.0, 35.6/34.0, 31.3/25.4; IR (KBr): ν (cm^{-1}) 2937, 1771, 1705, 1433, 1397, 1363, 1192, 1049, 935, 720, 533; EIMS: m/z (rel intensity) 323 (17), 321 (M^+ , 18), 280 (3), 242 (5), 201 (4), 160 (100), 148 (47), 130 (16), 105 (36), 94 (12), 77 (25), 67 (8); HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{BrNO}_2$ [M]: 321.0364; found: 321.0368.




4-Bromo-1-tosylpiperidine. Yield: 44 mg (70%). White solid, mp: 132–134 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.65 (d, $J = 8.0$ Hz, 2H), 7.34 (d, $J = 8.0$ Hz, 2H), 4.27–4.21 (m, 1H), 3.24–3.16 (m, 2H), 3.14–3.05 (m, 2H), 2.44 (s, 3H), 2.23–2.14 (m, 2H), 2.09–2.01 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 143.7, 133.4, 129.8, 127.6, 47.8, 43.8, 34.7, 21.5; IR (KBr): ν (cm^{-1}) 2920, 1596, 1342, 1164, 1092, 928, 859, 812, 745, 713, 697, 651, 578, 551; EIMS: m/z (rel intensity) 319 (5), 317 (M^+ , 6), 238 (70), 184 (51), 155 (73), 91 (100), 82 (14), 65 (17), 42 (19); HRMS calcd for $\text{C}_{12}\text{H}_{16}\text{BrNO}_2\text{S}$ [M]: 317.0085; found: 317.0083.




(4-Bromopiperidin-1-yl)(4-(trifluoromethyl)phenyl)methanone. Yield: 50 mg (75%). Colorless oil; ^1H NMR (400 MHz, CDCl_3): δ 7.69 (d, $J = 8.0$ Hz, 2H), 7.52 (d, $J = 8.0$ Hz, 2H), 4.48–4.42 (m, 1H), 3.95 (br, 1H), 3.80 (br, 1H), 3.62 (br, 1H), 3.32 (br, 1H), 2.22 (br, 1H), 2.07 (br, 2H), 1.94 (br, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 169.0, 139.2, 131.8 (q, $J = 32.0$ Hz), 127.2, 125.7 (q, $J = 3.6$ Hz), 123.7 (q, $J = 271.0$ Hz), 48.4, 45.6, 40.2, 36.0, 35.1; ^{19}F NMR (376 MHz, CDCl_3): δ -62.9 (s, 3F); IR (neat): ν (cm^{-1}) 2957, 2868, 1639, 1440, 1325, 1281, 1203, 1167, 1128, 1065, 999, 851; EIMS: m/z (rel intensity) 337 (18), 336 (41), 335 (17), 334 (42), 318 (4), 256


(17), 173 (100), 145 (34), 86 (30), 84 (46); HRMS calcd for $C_{13}H_{12}BrF_3NO$ [M-H]: 334.0054; found: 334.0055.



2-Bromo-2-methylpropane-1,3-diyl diacetate. Yield: 45 mg (89%). Colorless oil; 1H NMR (400 MHz, $CDCl_3$): δ 4.34 (d, $J = 12.0$ Hz, 2H), 4.26 (d, $J = 12.0$ Hz, 2H), 2.11 (s, 6H), 1.76 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 170.1, 68.4, 60.0, 25.6, 20.7; IR (neat): ν (cm^{-1}) 2934, 1749, 1461, 1378, 1235, 1055, 1034, 900, 645, 602; EIMS: m/z (rel intensity) 173 (26), 131 (22), 122 (27), 120 (27), 113 (52), 103 (33), 71 (16), 43 (100); HRMS calcd for $C_6H_{10}BrO_3$ [M-COCH₃]: 208.9813; found: 208.9815.




Cyclohexyl 4-bromo-4-methylpentanoate. Yield: 46 mg (83%). Colorless oil; 1H NMR (400 MHz, $CDCl_3$): δ 4.80–4.74 (m, 1H), 2.59–2.53 (m, 2H), 2.14–2.09 (m, 2H), 1.87–1.83 (m, 2H), 1.76 (s, 6H), 1.74–1.69 (m, 2H), 1.58–1.52 (m, 1H), 1.47–1.20 (m, 5H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 172.5, 72.8, 66.4, 41.9, 34.2, 32.1, 31.6, 25.4, 23.8; IR (neat): ν (cm^{-1}) 2936, 2859, 1774, 1730, 1450, 1170, 1108, 1015; EIMS: m/z (rel intensity) 197 (5), 195 (5), 179 (7), 177 (7), 115 (100), 97 (37), 82 (14), 69 (32), 55 (17), 41 (12); HRMS calcd for $C_{10}H_{22}BrO_2$ [M+H]: 277.0803; found: 277.0799.




(4-Bromo-4-methylpiperidin-1-yl)(phenyl)methanone. Yield: 52 mg (92%). Colorless oil; 1H NMR (400 MHz, $CDCl_3$): δ 7.43–7.38 (m, 5H), 4.63 (br, 1H), 3.67 (br, 1H), 3.47 (br, 1H), 3.25 (br, 1H), 2.13 (br, 1H), 1.98 (br, 1H), 1.89 (s, 3H), 1.71 (br, 1H), 1.55 (br, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 170.4, 135.9, 129.7, 128.5,


126.9, 67.2, 45.3, 42.3, 41.5, 39.7, 34.9; IR (neat): ν (cm⁻¹) 2945, 2928, 1633, 1430, 1286, 1250, 1125, 1099, 966, 708; EIMS: m/z (rel intensity) 282 (9), 280 (9), 202 (11), 201 (21), 200 (7), 106 (9), 105 (100), 77 (36), 51 (10), 41 (6); HRMS calcd for C₁₃H₁₅BrNO [M-H]: 280.0337; found: 280.0344.




1-(Bromomethyl)-3-(trifluoromethoxy)benzene. Yield: 44 mg (87%). Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ 7.37 (t, J = 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.25 (s, 1H), 7.15 (d, J = 8.0 Hz, 1H), 4.47 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 149.4 (q, J = 1.5 Hz), 139.9, 130.2, 127.3, 121.5, 120.8, 120.4 (q, J = 256.0 Hz), 31.9; ¹⁹F NMR (376 MHz, CDCl₃): δ -57.8 (s, 3F); IR (neat): ν (cm⁻¹) 2926, 2855, 1612, 1591, 1488, 1448, 1253, 1216, 1165, 795, 691, 632; EIMS: m/z (rel intensity) 256 (10), 254 (M⁺, 10), 176 (11), 175 (100), 109 (31), 83 (14), 78 (9), 77 (5), 69 (4); HRMS calcd for C₈H₆BrF₃O [M]: 253.9554; found: 253.9552.




2-Bromo-2-phenylethyl acetate. Yield: 44 mg (91%). Colorless oil; ¹H NMR (400 MHz, CDCl₃): δ 7.43–7.29 (m, 5H), 5.12 (t, J = 7.2 Hz, 1H), 4.60 (dd, J = 11.6, 7.2 Hz, 1H), 4.51 (dd, J = 11.6, 7.2 Hz, 1H), 2.04 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 170.4, 138.1, 129.0, 128.9, 127.8, 67.5, 49.9, 20.7; IR (neat): ν (cm⁻¹) 3028, 3021, 2933, 1746, 1454, 1366, 1232, 1038, 763, 698; EIMS: m/z (rel intensity) 184 (30), 182 (29), 163 (100), 120 (25), 117 (35), 107 (57), 104 (40), 103 (52), 91 (23), 79 (28), 77 (27), 43 (82); HRMS calcd for C₁₀H₁₁BrO₂ [M]: 241.9942; found: 241.9944.



(Bromo(cyclohexyl)methyl)benzene. Yield: 46 mg (92%). Colorless oil; ^1H NMR (400 MHz, CDCl_3): δ 7.36–7.23 (m, 5H), 4.70 (d, $J = 8.8$ Hz, 1H), 2.33–2.28 (m, 1H), 2.01–1.91 (m, 1H), 1.83–1.77 (m, 1H), 1.65–1.61 (m, 2H), 1.50–1.45 (m, 1H), 1.34–0.98 (m, 4H), 0.90–0.78 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 141.5, 128.4, 128.0, 127.9, 63.3, 45.4, 32.2, 31.0, 26.2, 26.0, 25.9; IR (neat): ν (cm^{-1}) 2924, 2854, 1462, 1379, 1285, 1200, 797, 721; EIMS: m/z (rel intensity) 174 (11), 173 (73), 130 (15), 129 (14), 128 (13), 117 (13), 115 (32), 105 (15), 91 (100), 81 (11); HRMS calcd for $\text{C}_{13}\text{H}_{17}\text{Br}$ [M]: 252.0514; found: 252.0518.




Ethyl 2-(bromomethyl)-3,3-diphenylacrylate. Yield: 36 mg (52%). White solid, mp: 95–97 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.40–7.34 (m, 5H), 7.31–7.26 (m, 3H), 7.12–7.08 (m, 2H), 4.32 (s, 2H), 4.01 (q, $J = 7.2$ Hz, 2H), 0.89 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 168.6, 151.3, 141.6, 139.6, 129.1, 128.9, 128.86, 128.83, 128.5, 128.4, 128.0, 61.1, 32.5, 13.6; IR (KBr): ν (cm^{-1}) 2926, 1712, 1598, 1490, 1444, 1367, 1327, 1260, 1150, 1102, 1019, 766, 700; EIMS: m/z (rel intensity) 346 (1), 344 (M^+ , 1), 265 (100), 219 (44), 192 (57), 191 (94), 190 (24), 189 (38), 165 (27), 115 (32), 91 (11); HRMS calcd for $\text{C}_{18}\text{H}_{17}\text{BrO}_2$ [M]: 344.0412; found: 344.0418.




(5R,8R,9S,10S,13R,14S)-17-((2R)-4-bromopentan-2-yl)-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one. Yield: 72 mg (85%). This compound was isolated as the mixture of two stereoisomers in about 1:1 ratio determined by ^1H NMR (400 MHz). White solid, mp: 118–120 °C; ^1H NMR (400 MHz, CDCl_3) (mixture of two stereoisomers): δ 4.30–4.15 (m, 1H), 2.69 (t, $J = 14.4$ Hz, 1H), 2.33 (td, $J = 14.4, 5.2$ Hz, 1H), 2.19–2.12 (m, 1H), 2.08–1.06 (m, 29H), 0.93 (dd, $J = 6.4$,

2.4 Hz, 3H), 0.73 (s, 1.5H), 0.69 (s, 1.5H); ^{13}C NMR (100 MHz, CDCl_3): δ 213.2, 213.1, 56.7, 56.50, 56.48, 56.39, 50.6, 49.1, 48.4, 47.6, 44.3, 42.9, 42.3, 40.75, 40.70, 40.12, 40.06, 37.2, 37.0, 35.5, 35.1, 34.9, 28.4, 28.1, 27.6, 26.6, 25.8, 25.7, 25.4, 24.1, 22.67, 22.65, 21.20, 21.18, 18.4, 18.1, 12.2, 12.1; IR (KBr): ν (cm^{-1}) 2937, 2865, 1714, 1445, 1378, 1265, 912, 733, 531; EIMS: m/z (rel intensity) 424 (11), 422 (M^+ , 11), 354 (18), 352 (18), 231 (100), 176 (49), 161 (62), 107 (52), 95 (72), 81 (74), 79 (53), 67 (56), 55 (76), 41 (53); HRMS calcd for $\text{C}_{24}\text{H}_{39}\text{BrO}$ [M]: 422.2184; found: 422.2182.




***cis*-(2-Bromocyclohexyl)(phenyl)methanone.** Yield: 20 mg (38%). White solid, mp: 86-88 °C; ^1H NMR (400 MHz, CDCl_3): 7.83 (d, J = 7.6 Hz, 2H), 7.56 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 4.73 (d, J = 3.2 Hz, 1H), 3.54 (dt, J = 10.8, 3.2 Hz, 1H), 2.27-2.23 (m, 1H), 2.07-1.98 (m, 2H), 1.92-1.77 (m, 3H), 1.64-1.59 (m, 1H), 1.46-1.34 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 200.0, 136.3, 132.7, 128.8, 128.1, 54.3, 49.6, 35.0, 24.2, 22.8, 21.1; IR (KBr): ν (cm^{-1}) 2937, 2859, 1687, 1597, 1446, 1255, 965, 697, 659; EIMS: m/z (rel intensity) 187 (18), 105 (100), 82 (11), 77 (28), 67 (6), 51 (7); HRMS calcd for $\text{C}_{13}\text{H}_{15}\text{BrO}$ [M]: 266.0306; found: 266.0309.



***trans*-(2-Bromocyclohexyl)(phenyl)methanone.** Yield: 20 mg (38%). Colorless oil; ^1H NMR (400 MHz, CDCl_3): δ 7.99 (d, J = 7.6 Hz, 2H), 7.58 (t, J = 7.6 Hz, 1H), 7.48 (t, J = 7.6 Hz, 2H), 4.48-4.41 (m, 1H), 3.84-3.79 (m, 1H), 2.51-2.47 (m, 1H), 2.01-1.93 (m, 2H), 1.84-1.80 (m, 2H), 1.48-1.40 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 201.0, 136.3, 133.3, 128.7, 128.4, 54.0, 51.4, 37.4, 31.9, 26.9, 24.8; IR (neat): ν (cm^{-1}) 2935, 2858, 1681, 1447, 1262, 1180, 959, 699, 662; EIMS: m/z (rel

intensity) 268 (1), 266 (M^+ , 1), 187 (32), 105 (100), 82 (11), 77 (23), 67 (5), 51 (5); HRMS calcd for $C_{13}H_{15}BrO [M]$: 266.0306; found: 266.0314.



Ethyl 2-bromo-2-(4-methyl-1-tosylpyrrolidin-3-yl)acetate. This compound is the mixture of four stereoisomers. The two major isomers were purified by column chromatography on silica gel in about 2:1 ratio. While the other two isomers could not be obtained in pure forms. Data of the two major isomers (~2:1): Yield: 34 mg (42%). colorless oil; 1H NMR (400 MHz, $CDCl_3$): δ 7.72 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.25–4.17 (m, 2H), 4.15 (d, J = 7.2 Hz, 0.34H), 4.05 (d, J = 11.6, 0.66H), 3.63 (dd, J = 10.4, 8.0 Hz, 0.66H), 3.54–3.49 (m, 0.66H), 3.41–3.30 (m, 1H), 3.24–3.15 (m, 1.34H), 2.82–2.70 (m, 1H), 2.45 (s, 3H), 2.36–2.29 (m, 0.66H), 2.22–2.16 (m, 0.34H), 2.05–1.97 (m, 0.34H), 1.32–1.24 (m, 3H), 0.94 (d, J = 7.2 Hz, 1H), 0.76 (d, J = 7.2 Hz, 2H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 168.6, 143.7/143.6, 133.8/133.3, 129.8/129.7, 127.7/127.5, 62.3/62.2, 55.9/54.6, 51.0/50.5, 48.2/47.5, 45.4/44.1, 36.9/34.7, 21.5/16.8, 13.9/13.8, 13.2; IR (neat): ν (cm^{-1}) 2976, 2932, 1737, 1597, 1453, 1345, 1163, 1093, 1018, 815, 664, 592, 548; EIMS: m/z (rel intensity) 324 (2), 278 (12), 250 (44), 248 (26), 168 (75), 155 (40), 122 (16), 91 (100), 82 (24), 65 (19), 42 (38); HRMS calcd for $C_{16}H_{22}BrNO_4S [M]$: 403.0453; found: 403.0455.



5. References for Known Compounds.

entry	references	compound
1	Wang, Z.; Zhu, L.; Yin, F.; Su, Z.; Li, Z.; Li, C. <i>J. Am. Chem. Soc.</i> 2012 , <i>134</i> , 4258.	1a, 1b, 1k, 1s 1u, 1w, 1x, 8, 10
2	Yin, F.; Wang, Z.; Li, Z.; Li, C. <i>J. Am. Chem. Soc.</i> 2012 ,	1f, 1j, 1l, 1y, 4


	134, 10401.	
3	Liu, C.; Wang, X.; Li, Z.; Cui, L.; Li, C. <i>J. Am. Chem. Soc.</i> 2015 , 137, 9820.	1c, 1e, 1g
4	De, P.; Van, L. <i>J. Org. Chem.</i> 1974 , 39, 3360.	3d
5	Zhang, M.; Jia, T.; Sagamanova, I. K.; Pericas, M. A.; Walsh, P. J. <i>Org. Lett.</i> 2015 , 17, 1164.	3r, 3p, 3s
6	Landge, K. P.; Jang, K. S.; Lee, S. Y.; Chi, D. Y. <i>J. Org. Chem.</i> 2012 , 77, 5705.	3m
7	Frutos, O. D.; Rincon, J. A.; Mateos, C.; Kappe, C. O. <i>J. Org. Chem.</i> 2014 , 79, 223.	3n
8	Champagne, P. A.; Pomarole, J.; Therien, M. E.; Benhassine, Y.; Beaulieu, S.; Legault, C. Y.; Paquin, J. F. <i>Org. Lett.</i> 2013 , 15, 2210.	3q
9	Mizukami, Y.; Song, Z.; Takahashi, T. <i>Org. Lett.</i> 2015 , 17, 5942.	3i
10	Soloshonok, V. A.; Tang, X.; Hruby, V. J.; Meervelt, L. <i>V. Org. Lett.</i> 2001 , 3, 341.	3t
11	Wang, G.; Jiang, J.; Bu, X.; Dai, J.; Xu, J.; Fu, Y.; Xu, H. <i>Org. Lett.</i> 2015 , 17, 3682.	3y
12	Li, C.; Han, K.; Li, J.; Zhang, H.; Ma, J.; Shu, X.; Chen, Z.; Weng, L.; Jia, X. <i>Org. Lett.</i> 2012 , 14, 42.	3z
13	Adrio, L. A.; Quek, L. S.; Taylor, J. G.; Kuok, H. K. <i>Tetrahedron</i> 2009 , 65, 10334.	7


7. ¹H and ¹³C Spectra of All Products

Compound **3a**





Compound 3b








Compound 3c




Compound 3d





Compound 3e








Compound **3f**





Compound **3g**








Compound **3i**




Compound 3j





Compound 3k








Compound **3l**




Compound **3m**





Compound 3n








Compound 3o




Compound 3p





Compound 3q








Compound 3r




Compound 3s





Compound 3t








Compound **3u**




Compound **3v**





Compound 3w








Compound 3x




Compound 3y





Compound 3z








Compound 5




Compound 7





Compound *cis*-9





Compound *trans*-9



Compound 11

